Production (Stage)
Cartesian Therapeutics, Inc.
RNAC
$10.32
-$0.10-0.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.10M | -759.00K | 387.00K | 33.45M | 5.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.10M | -759.00K | 387.00K | 33.45M | 5.84M |
| Cost of Revenue | 14.67M | 11.31M | 11.40M | 12.66M | 9.54M |
| Gross Profit | -13.57M | -12.07M | -11.01M | 20.78M | -3.70M |
| SG&A Expenses | 8.32M | 7.09M | 6.56M | 7.03M | 9.35M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.99M | 18.39M | 17.96M | 19.69M | 18.89M |
| Operating Income | -21.89M | -19.15M | -17.58M | 13.76M | -13.05M |
| Income Before Tax | -17.71M | -9.97M | -24.18M | 13.84M | -56.82M |
| Income Tax Expenses | -- | 287.00K | -- | -- | -- |
| Earnings from Continuing Operations | -17.71M | -10.25M | -24.18M | 13.84M | -56.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.71M | -10.25M | -24.18M | 13.84M | -56.82M |
| EBIT | -21.89M | -19.15M | -17.58M | 13.76M | -13.05M |
| EBITDA | -20.73M | -18.67M | -17.29M | 13.95M | -12.87M |
| EPS Basic | -0.68 | -0.40 | -1.13 | 0.58 | -10.50 |
| Normalized Basic EPS | -0.44 | -0.43 | -0.26 | 0.42 | -1.99 |
| EPS Diluted | -0.68 | -0.42 | -1.13 | 0.54 | -10.50 |
| Normalized Diluted EPS | -0.44 | -0.43 | -0.26 | 0.40 | -1.99 |
| Average Basic Shares Outstanding | 25.90M | 25.42M | 21.47M | 16.72M | 5.41M |
| Average Diluted Shares Outstanding | 25.90M | 25.42M | 21.47M | 17.79M | 5.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |